Loading
X4 Pharmaceuticals, Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 27 Oct 2025.
X4 Pharmaceuticals, Inc: what insiders have been doing
Every trade that managers of X4 Pharmaceuticals, Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 7 filings signed by 6 insiders.
Purchases and sales both appear in the filings: 1 purchase (1 insider, €215k) and 3 sales (3 insiders, €307k). Taken together, the sales exceed the purchases by €92k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 chief executive among the declarants. One trade stands out by size: a purchase of €215k from Craig Adam R, disclosed on 27 October 2025.
With 7 filings in twelve months, the company is quieter than the median of 19 filings across the 5,808 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 4 purchases and 66 sales. The 10-K for the year ended 31 December 2025 shows 6.5 m USD of revenue and -79.2 m USD of net income.
The latest purchase dates back some time: it was published 356 days ago, on 27 October 2025. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
139
Thresholds
n/a
Buy Volume
€258,425
4 ops. · all time
Sell Volume
€1M
66 ops. · all time
Who traded when
BuySaleAdam R. Craig1 buy1 sale
David Kirske1 sale
John Volpone1 sale
Mark Baldry1 buy
Paula Ragan1 sale
Since the insiders bought
- -4.7%Entry US$3.81 · Close at T+90 US$3.63
- +45.8%Entry US$2.77 · Close at T+365 US$4.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,431 of 24,148 companies
27.2
score / 100
Value7
Quality48
FCF yld-35%
Earn yld-31%
EV/EBITDA·
ROE-113%
Gross mgn84%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.60
Analyst consensus
5 analysts1.00/5
US$10.00Target US$11.60(+346%)US$13.00
Income statement
RevenueUS$35.1M
Gross profitUS$29.4M84% margin
EBITDA-US$69M-197% margin
Net income-US$79.2M-225.6% margin
Valuation
PER (trailing)130.0x
PER (forward)-3.4x
P/Book1.6x
Beta0.46
Balance sheet & cash
Market capUS$257.8M
Total debtUS$77.3M
Free Cash Flow-US$88.6M
Debt / Equity50%
Profitability & ownership
ROE-113.1%
ROA-28.1%
% insiders0.4%
% institutions103.8%
Last declaration on 5 October 2026
Declarations139 total
11,767 shares@ US$2.86040.012% mcap100.0% of flowCommon StockSEC:0001501697-26-000078:0
11,767 shares@ US$2.86040.012% mcap100.0% of flowCommon StockSEC144:0001276750-26-000008
47,436 shares@ US$4.5550.071% mcap100.0% of flowCommon StockSEC144:0001339498-26-000003
24,576 shares@ US$4.5550.037% mcap100.0% of flowCommon StockSEC144:0002081729-26-000004
47,436 shares@ US$4.44450.070% mcap45.9% of flowCommon StockSEC:0001501697-26-000069:0
24,576 shares@ US$4.44450.036% mcap100.0% of flowCommon StockSEC:0001501697-26-000070:0
86,206 shares@ US$2.9054.1% of flowCommon StockSEC:0001501697-25-000035:0
Canonical exit: 21 Jan 2026 (T+90)
289,881 shares0Common StockSEC:0001628280-25-040444:0
289,881 shares0Common StockSEC:0001628280-25-040441:0
193,254 shares0Common StockSEC:0001628280-25-040440:0
3,333 shares0Common StockSEC:0001628280-25-034233:0
1,500 shares0Common StockSEC:0001628280-25-030504:0
1,500 shares0Common StockSEC:0001628280-25-030503:0
1,500 shares0Common StockSEC:0001628280-25-030492:0
1,500 shares0Common StockSEC:0001628280-25-030489:0
1,500 shares0Common StockSEC:0001628280-25-030502:0
1,500 shares0Common StockSEC:0001628280-25-030500:0
1,032 shares@ US$2.4828.0% of flowCommon StockSEC:0001628280-25-026864:0
Canonical exit: 14 Aug 2025 (T+90)
21,646 shares@ US$0.67746.9% of flowCommon StockSEC:0001628280-25-005698:0
Canonical exit: 15 Aug 2024 (T+90)
650,000 shares0Common StockSEC:0001628280-25-005696:0
850,000 shares0Common StockSEC:0001628280-25-005702:0
2,250,000 shares0Common StockSEC:0001628280-25-005700:0
850,000 shares0Common StockSEC:0001628280-25-005704:0
25,831 shares0Common StockSEC:0001628280-25-002705:0
74,773 shares0Common StockSEC:0001628280-25-002707:0
25 of 139 declarations
About X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq (XFOR) in the United States, focused on developing and commercializing innovative therapies for rare immune-system and hematology disorders linked to CXCR4 biology. The company is headquartered in Boston, Massachusetts. Its roots go back to a CXCR4-focused scientific platform and a licensing foundation with Sanofi/Genzyme, and the modern company was shaped through the merger with Arsanis and a subsequent refocusing on high-unmet-need rare disease programs. X4 was founded in 2014. ([investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-completes-merger-arsanis/?utm_source=openai))
X4’s lead asset is mavorixafor, an oral selective CXCR4 antagonist. The drug is marketed in the United States as XOLREMDI® for WHIM syndrome, a rare primary immunodeficiency. That makes X4 more than a pure clinical-stage story: it has moved into a partially commercial biopharma model, although the company’s value remains heavily concentrated in a single lead asset. Management also states that it is running the pivotal Phase 3 4WARD trial in chronic neutropenic disorders, supported by FDA Fast Track designation for mavorixafor in chronic neutropenia. ([investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
Read moreShow less
From a competitive standpoint, X4 is a specialist rather than a broad-platform pharma company. Its differentiation comes from CXCR4 biology and its focus on rare diseases with limited treatment options, which can support meaningful clinical and commercial exclusivity if development succeeds. At the same time, this concentration creates high execution risk: the investment case depends disproportionately on regulatory milestones, adoption of XOLREMDI, and the outcome of the company’s key clinical program. X4 previously explored additional CXCR4 programs, including oncology and preclinical initiatives, but it has narrowed its focus to maximize value around its core asset. ([investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-strategic-restructuring-drive-value?utm_source=openai))
Recent developments underscore that strategy. In its first-quarter 2026 update, X4 said its top priority remains execution and full enrollment of the pivotal 4WARD study, and it noted that net product sales were primarily driven by U.S. sales of XOLREMDI. In early 2026, the company also reported full-year 2025 results and a corporate update, reinforcing that the story is centered on rare hematology and continued development progress. For French-speaking investors, X4 should be viewed as a specialty small-cap biotech on the Nasdaq in the United States, with a concentrated pipeline, a commercial foothold in a rare disease, and a valuation that will likely remain highly sensitive to clinical, regulatory, and launch execution milestones. ([investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-reports-first-quarter-2026-financial-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
